Managed care organizations (MCOs) experienced a 1.7% drug overall trend, a 10.5% reduction from 2012 to 2013, according to Catamaran’s 2013 Drug Trend data. In 2012, MCO trend was 1.9%.
FDA approved albiglutide (Tanzeum, GlaxoSmithKline), a once-weekly subcutaneous injectable for the treatment of adults with type 2 diabetes. It helps to improve glycemic control, along with diet and exercise.
Despite strong FDA warnings against its use in adolescents, a new study suggests that codeine is prescribed for children during at least 500,000 emergency room (ER) visits each year.
FDA approved Short Ragweed Pollen Allergen Extract (Ragwitek, Merck) the first sublingual allergen extract to treat short ragweed pollen induced allergic rhinitis (hay fever), with or without conjunctivitis (eye inflammation), in adults aged 18 years through 65 years.
FDA has approved a new indication for ofatumumab (Arzerra, GlaxoSmithKline and Genmab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.